



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/083,476	02/27/2002	Roger N. Piasio	ISA-102.01	4777
63767	7590	03/05/2009	EXAMINER	
FOLEY HOAG, LLP			DEVI, SARVAMANGALA J N	
PATENT GROUP (w/ISA)			ART UNIT	PAPER NUMBER
155 SEAPORT BLVD.			1645	
BOSTON, MA 02210-2600				
MAIL DATE		DELIVERY MODE		
03/05/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/083,476	PIASIO ET AL.	
	Examiner S. Devi, Ph.D.	Art Unit 1645	
All Participants:		Status of Application: _____	
(1) <u>S. Devi (PTO)</u>		(3) _____.	
(2) <u>Jannan Ali</u> .		(4) _____.	
Date of Interview: <u>27 February 2009</u>		Time: _____	
Type of Interview:			
<input checked="" type="checkbox"/> Telephonic <input type="checkbox"/> Video Conference <input type="checkbox"/> Personal (Copy given to: <input type="checkbox"/> Applicant <input type="checkbox"/> Applicant's representative)			
Exhibit Shown or Demonstrated: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No If Yes, provide a brief description: <i>Examples 3 and 4; Tables III and IV, and pages 14-16 of the application.</i>			
Part I.			
Rejection(s) discussed:			
Claims discussed:			
<i>Claim 22</i>			
Prior art documents discussed:			
Part II.			
SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:			
<i>See Continuation Sheet</i>			
Part III.			
<input type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. <input checked="" type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.			
(Applicant/Applicant's Representative Signature – if appropriate)			

Continuation of Substance of Interview including description of the general nature of what was discussed: The capture line and/or scrub line antibody concentrations as disclosed in Examples 3 and 4 and Tables III and IV and the description on pages 14-16 of the application were discussed. Applicant was informed that the disclosures herein do not appear to indicate that the test method maintains the intended test specificity of 90% or more and an increased sensitivity of the test to infected subjects, while eliminating or minimizing false positives in nasopharyngeal colonizers to an acceptable level. Applicants would address this issue in response to the non-final Office action being issued.

/S. Devi, Ph.D./
Primary Examiner, Art Unit 1645

02/27/2009